Biocartis this week announced that it is in the testing phase of a Rapid Ebola Virus Triage Test that it is developing in association with Janssen Diagnostics and the Institute for Tropical Medicine in Antwerp.
The test is for use on the Biocartis Idylla system, a fully automated PCR molecular diagnostic platform that is CE-IVD marked in Europe.
The Rapid Ebola Virus Triage Test is designed to enable healthcare workers, even in challenging environments, to test blood samples and aims at providing accurate and fast diagnosis of Ebola. The test is designed to offer a unique combination of speed, sensitivity, accuracy and ease-of-use required for outbreaks where time is of the essence.
The test uses 0,2 ml blood that is added directly to the Idylla cartridge, which contains all necessary reagents on board for performing the analysis on Biocartis’ fully automated, molecular diagnostics system. A complete analysis of the sample takes around 90 minutes and can be operated by healthcare professional in most settings, including in the field, making the test ideal for use in regions with limited infrastructure.
“One of the lessons of the Ebola outbreak has been the urgent need for faster and more accurate diagnostics,” Rudi Pauwels, Biocartis’ Chief Executive Officer commented. Biocartis is pleased to be working, alongside prestigious partners, on what it believes could offer a viable solution for healthcare workers around the world to enable faster testing of infectious diseases in virtually any setting.”
Biocartis believes its Rapid Ebola Virus Triage Test could provide a sustainable solution for rapid detection of Ebola-infected patients even after the current Ebola outbreak. After testing of synthetic virus samples in Belgium and the US, Biocartis has now registered for field-testing in West Africa to gather additional clinical evidence for the test performance.